Oxford researchers find malaria vaccine target

Scientists at the University of Oxford have identified a potential malaria vaccine that succeeded in neutralizing all strains of Plasmodium falciparum, the most deadly form of the disease, in animals. The study confirmed earlier research that identified the antigen RH5 as a target for malaria vaccine researchers. Release

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.